Associated tags: Health, Retail, Pharmaceutical, Cosmetics, Luxury, General Health, Women, Consumer, Pharmaceutical industry, Biotechnology
Locations: BOSTON, DALLAS, TEXAS, JAPAN, UNITED STATES, NORTH AMERICA, CALIFORNIA, SAN FRANCISCO, AUSTRIA, GERMANY, EUROPE, SPAIN, ITALY, AUSTRALIA
Cosmetics,
Lifestyle,
Retail,
Health,
Consumer,
Pharmaceutical,
FDA,
Depreciation,
Patient,
PMA,
Growth,
Pharmaceutical industry Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
Key Points:
- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
- Operating expenses for the first quarter of 2024 were $68.3 million, compared to $69.6 million in the fourth quarter of 2023.
- Non-GAAP operating expenses for the first quarter of 2024 were $42.1 million, compared to $45.5 million in the fourth quarter of 2023.
- Loss from operations for the first quarter of 2024 was $8.9 million, compared to $8.6 million in the fourth quarter of 2023.
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May 7, 2024, after the U.S. financial markets close.
Key Points:
- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May 7, 2024, after the U.S. financial markets close.
- Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m.
- A question-and-answer session will follow management’s remarks.
- To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here .
Retrieved on:
Wednesday, April 17, 2024
Pharmaceutical,
Health,
Clinical Trials,
Sale,
Safety,
MD,
Patient,
AB toxin,
Aesthetic Surgery Journal,
GLS,
Overalls,
Pharmaceutical industry The “extra-strength” glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction.
Key Points:
- The “extra-strength” glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction.
- The study has three arms: Jeuveau® Extra-Strength 40U and two active controls, BOTOX® 20U and Jeuveau® 20U.
- The safety profile was similar across all three arms and overall, 88.9% of adverse events were rated as mild and no serious adverse events were identified.
- “This publication provides the details of the study design along with the efficacy and safety data from the Phase 2 Jeuveau extra-strength study and makes it accessible to all,” said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D of Evolus.
Other Health,
Other Retail,
Pharmaceutical,
Luxury,
Consumer,
Cosmetics,
Retail,
Public Relations,
Investor Relations,
Women,
Biotechnology,
Communications,
Health,
RSU,
Employment The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant and vesting commencement date of April 7, 2024, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).
Key Points:
- The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant and vesting commencement date of April 7, 2024, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).
- The stock options have an exercise price of $13.26 per share, the closing price of Evolus’ common stock on the trading day preceding the date of grant.
- The stock options have a 10-year term and vest over 4 years, with 25% of the number of shares subject to the option vesting on each annual anniversary of the vesting commencement date.
- The RSUs vest 25% on each annual anniversary of the vesting commencement date.
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conference in April:
Key Points:
- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conference in April:
The fireside chat can be accessed on the Investor Relations page of the Evolus website here .
- A replay of the webcast will be available for 90 days following the presentation.
Cosmetics,
Retail,
Pharmaceutical,
Health,
SVB Securities,
Montgomery Street,
Growth,
Form,
Telephone,
EDGAR,
Sale,
Attention,
Prospectus,
State Street Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal to the closing price on Friday, March 8, 2024, before underwriting discounts and commissions.
Key Points:
- Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal to the closing price on Friday, March 8, 2024, before underwriting discounts and commissions.
- The gross proceeds from the offering to Evolus are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and offering expenses.
- In addition, Evolus has granted the underwriters a 30-day option to purchase up to an additional 533,100 shares of common stock at the underwritten offering price, less the underwriting discounts and commissions.
- The offering was made pursuant to the prospectus accompanying Evolus’ registration statement on Form S-3 (File No.
The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant and vesting commencement date of March 7, 2024, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).
Key Points:
- The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant and vesting commencement date of March 7, 2024, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).
- The stock options have an exercise price of $14.79 per share, the closing price of Evolus’ common stock on the date of grant.
- The stock options have a 10-year term and vest over 4 years, with 25% of the number of shares subject to the option vesting on each annual anniversary of the vesting commencement date.
- The RSUs vest 25% on each annual anniversary of the vesting commencement date.
Women,
Other Retail,
Men,
Specialty,
Lifestyle,
Consumer,
Cosmetics,
Retail,
International,
PMA,
FDA,
Growth,
IPR,
Depreciation,
Pharmaceutical industry Accounts purchasing Jeuveau® increased by a record high of more than 840 in the fourth quarter.
Key Points:
- Accounts purchasing Jeuveau® increased by a record high of more than 840 in the fourth quarter.
- Loss from operations for the fourth quarter of 2023 was $8.6 million, compared to $13.4 million in the third quarter of 2023.
- Non-GAAP loss from operations in the fourth quarter of 2023 was $3.7 million, compared to $5.7 million in the third quarter of 2023.
- Evolus expects its adjusted gross profit margin for the full year 2024 to be between 68% and 71%, consistent with 2023 guidance.
Biotechnology,
Pharmaceutical,
Surgery,
Health,
Fitness & Nutrition,
Cosmetics,
Clinical Trials,
Retail,
NLF,
MD,
FDA,
Skin,
Nasolabial fold,
Webcast,
Patient,
Longevity Evolus remains on track for the global commercial launch of the first-generation Cold HA Technology in 2025.
Key Points:
- Evolus remains on track for the global commercial launch of the first-generation Cold HA Technology in 2025.
- The filler line will be branded Evolysse™ in the US and Estyme® in the UK and Europe.
- The Evolysse™/Estyme® Lift filler will be positioned as the most versatile and highest volume filler in the product line.
- An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com .
Retrieved on:
Tuesday, February 27, 2024
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conferences in March.
Key Points:
- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conferences in March.
- The fireside chats can be accessed on the Investor Relations page of the Evolus website here .
- A replay of the webcast will be available for 90 days after the date of the presentation.
